本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据2025年12月7日国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保险、生育保险和工 伤保险药品目录（2025年）》（以下简称"2025年国家医保目录"）以及首次发布的《商业健康保险创新 药品目录（2025年）》（以下简称"商保创新药目录"），上海复星医药（集团）股份有限公司及控股子 公司/单位（以下简称"本集团"）多款已上市产品获首次纳入或涉及备注信息调整，现将有关情况公告 如下： 一、新获纳入或涉及备注信息调整的主要品种 ■ 2025年国家医保目录、商保创新药目录将于2026年1月1日起执行。其中，2025年国家医保目录的具体医 保支付标准、医保报销细则、谈判药品的协议有效期等信息，须以国家医疗保障局等相关政府部门公示 信息为准。 前述新获纳入或涉及备注信息调整的药品2024年度及2025年前三季度的销售额合计分别约为人民币4.01 亿元、8.92亿元，分别约占同期本集团营业收入的0.98%、3.04%。本次新获纳入2025年国家医保目录/ 商保创新药目录将有利于 ...

证券代码：600196 股票简称：复星医药 编号：临2025-192 上海复星医药（集团）股份有限公司 关于公司药品新纳入国家医保目录及商保创新药目录的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据2025年12月7日国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保险、生育保险和工 伤保险药品目录（2025年）》（以下简称"2025年国家医保目录"）以及首次发布的《商业健康保险创新 药品目录（2025年）》（以下简称"商保创新药目录"），上海复星医药（集团）股份有限公司及控股子 公司/单位（以下简称"本集团"）多款已上市产品获首次纳入或涉及备注信息调整，现将有关情况公告 如下： 一、新获纳入或涉及备注信息调整的主要品种 ■ 2025年国家医保目录、商保创新药目录将于2026年1月1日起执行。其中，2025年国家医保目录的具体医 保支付标准、医保报销细则、谈判药品的协议有效期等信息，须以国家医疗保障局等相关政府部门公示 信息为准。 前述新获纳入或涉及备注信息调整的药品2024年度及2025年前三季度的销 ...

Core Viewpoint - The 2025 National Medical Insurance Drug List has been announced, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as oncology and chronic diseases [4][9]. Group 1: Drug List Adjustments - The 2025 National Medical Insurance Drug List will be implemented on January 1, 2026, with a total of 3,253 drugs, including 1,857 Western medicines and 1,396 traditional Chinese medicines [4]. - The list includes 50 first-class innovative drugs and removes 29 drugs that are either not clinically available or can be replaced by better alternatives [4]. Group 2: Impact on A-Share Companies - 15 A-share pharmaceutical companies announced that their products were included in the new drug list, particularly benefiting innovative drug companies [6]. - Zai Lab's drug, Jikaxitinib, was included, which is used for treating specific types of myelofibrosis, enhancing its market accessibility and sales potential [6]. - Junshi Biosciences reported that its products, including Toripalimab and Oncorine, were added to the list, with all four of its commercialized products now covered [6]. Group 3: Major Pharmaceutical Companies - Leading A-share pharmaceutical companies like Fosun Pharma, Hengrui Medicine, and others have also had products included in the new list, with Hengrui having 10 drugs added and several others with new indications [7]. - Hengrui's drugs are projected to generate approximately 8.66 billion yuan in sales for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [8]. Group 4: Complementary Innovations - In addition to the basic medical insurance list, 19 drugs have been added to the first version of the commercial insurance innovative drug list, including treatments for rare diseases and Alzheimer's, providing a complementary framework to the basic insurance [9].

Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are no longer clinically available or can be replaced by better alternatives [2][5]. Group 1: New Additions to the Drug List - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting many innovative drug companies [5]. - Zai Lab's drug, Jikaxitinib, has been included in the National Medical Insurance Drug List, which is expected to enhance sales and improve patient accessibility [5][6]. - Junshi Biosciences has added two new indications for its drug, Toripalimab, and successfully included another drug, Oncorine, in the Class B category of the National Medical Insurance List [5]. Group 2: Impact on Major Pharmaceutical Companies - Leading A-share pharmaceutical companies such as Fosun Pharma, East China Pharmaceutical, and Hengrui Medicine have also had products included in the National Medical Insurance List [7]. - Hengrui Medicine has 10 drugs newly added to the list, with a total sales revenue of approximately 8.66 billion yuan in 2024 and about 7.55 billion yuan in the first three quarters of 2025 [8]. - The inclusion of these drugs in the National Medical Insurance List is expected to positively impact sales, although the exact effect on operating performance is currently uncertain [8]. Group 3: Overall Changes in the Drug List - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2]. - This adjustment marks the 8th update since the establishment of the National Medical Insurance Bureau, indicating ongoing efforts to enhance drug accessibility and affordability [8].

Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as cancer, chronic diseases, and rare diseases [4][5][10]. Group 1: New Drug Inclusion - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting innovative drug companies [7]. - Zai Lab's drug, Jikaxitinib, has been included in the list, which is expected to enhance sales and market accessibility for patients [7]. - Junshi Biosciences has multiple products included, with two new indications for its drug Toripalimab and another drug successfully included in the Class B category [7]. Group 2: Impact on Major Pharmaceutical Companies - Leading companies like Hengrui Medicine have had 10 products included in the new list, with an estimated combined sales of approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [9]. - Other major players such as Fosun Pharma and Huadong Medicine also have products included, indicating a broad impact across the industry [8]. Group 3: Overall Drug List Changes - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [5]. - The adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and affordability [10].

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

2025 年国家医保目录、商保创新药目录将于2026年1月1日起执行。其中， 2025 年国家医保目录的具体医保支付标准、医保报 销细则、谈判药品的协议有效期等信息，须以国家医疗保障局等相关政府部门公示信息为准。 前述新获纳入或涉及备注信息调整的药品2024年度及2025年前三季度的销售额合计分别约为人民币4.01亿元、8.92亿元，分别 约占同期本集团营业收入的0.98%、3.04%。本次新获纳入2025年国家医保目录/商保创新药目录将有利于进一步提升该等药品 的可及性、减轻患者用药负担，同时也将有助于推动该等药品的市场推广和销售，预计将对本集团后续年度业绩产生积极影 响。 智通财经APP讯，复星医药(02196)发布公告，根据2025年12月7日国家医疗保障局、人力资源社会保障部发布的《国家基本医 疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称"2025 年国家医保目录")以及首次发布的《商业健康保险创新药品 目录(2025年)》(以下简称"商保创新药目录")，上海复星医药(集团)股份有限公司及控股子公司/单位(以下简称"本集团")多款已 上市产品获首次纳入或涉及备注信息调整，现将有关情况公 ...

2025年国家医保目录、商保创新药目录将于2026年1月1日起执行。其中，2025年国家医保目录的具体医保支付标准、医保报 销细则、谈判药品的协议有效期等信息，须以国家医疗保障局等相关政府部门公示信息为准。 复星医药（600196）(02196)发布公告，根据2025年12月7日国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保 险、生育保险和工伤保险药品目录(2025年)》(以下简称"2025年国家医保目录")以及首次发布的《商业健康保险创新药品目录 (2025年)》(以下简称"商保创新药目录")，上海复星医药(集团)股份有限公司及控股子公司/单位(以下简称"本集团")多款已上市 产品获首次纳入或涉及备注信息调整，现将有关情况公告如下： | 情形 | 药品名称 | 中国境内 | 中国境内 | | --- | --- | --- | --- | | | | 商品名 | 首次获批上市时间 | | 2025 年国家医保目录 | | | | | 新纳入 | 芦沃美替尼片 | 复迈宁 | 2025年5月 | | 枸橡酸伏维西利胶囊 | | 复妥宁 | 2025年5月 | | 吡仑帕奈口服混悬液 | | 奥捷宁 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲載列上海復星醫藥（ 集團 ）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 公司藥品新納入國家醫保目錄及商保創新藥目錄的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 证券代码：600196 股票简称：复星医药 编号：临 2025-192 上海复星医药（集团）股份有限公司 关于公司药品新纳入国家医保目录 董事長 陳玉卿 中國，上海 2025年12月7日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司 之 ...

人民财讯12月7日电，复星医药（600196）12月7日公告，根据12月7日国家医保局、人社部发布的《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》(简称"2025年国家医保目录")以及首次发布的《商业健康 保险创新药品目录(2025年)》(简称"商保创新药目录")，公司及控股子公司/单位多款已上市产品获首次纳入或 涉及备注信息调整。公司芦沃美替尼片等药品新纳入国家医保目录，阿基仑赛注射液新纳入商保创新药目 录。 | 情形 | 药品名称 | 中国境内* | 中国境内 * | | --- | --- | --- | --- | | | | 商品名 | 首次获批上市时间 | | 2025 年国家医保目录 | | | | | 新纳入 | 芦沃美替尼片 | 复迈宁 | 2025年5月 | | 枸橡酸伏维西利胶囊 | | 复要宁 | 2025年5月 | | 吡仑帕奈口服混悬液 | | 奥捷宁 | 2025年9月 | | 盐酸替那帕诺片 | | 万缇乐 | 2025年2月 | | 普托马尼片 | | 普瑞尼 | 2024 年 12 月 | | 备注信息调整 (新增活应症) | 盐酸凯普拉生片 | 倍稳 | ...